Insider Selling: Kura Oncology, Inc. (NASDAQ:KURA) COO Sells 1,817 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,817 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $14,299.79. Following the transaction, the chief operating officer now directly owns 21,367 shares of the company’s stock, valued at approximately $168,158.29. This trade represents a 7.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kathleen Ford also recently made the following trade(s):

• On Monday, November 18th, Kathleen Ford sold 526 shares of Kura Oncology stock. The shares were sold at an average price of $16.03, for a total value of $8,431.78.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $8.03 on Friday. The business’s 50 day moving average price is $9.02 and its 200-day moving average price is $15.58. Kura Oncology, Inc. has a 1 year low of $6.98 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $624.41 million, a PE ratio of -3.40 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the firm earned ($0.50) earnings per share. As a group, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KURA. nVerses Capital LLC purchased a new position in Kura Oncology during the third quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Kura Oncology in the third quarter valued at about $146,000. Quarry LP acquired a new stake in Kura Oncology during the second quarter worth about $196,000. Finally, Erste Asset Management GmbH purchased a new position in Kura Oncology during the third quarter worth about $215,000.

Analyst Ratings Changes

Several research firms have commented on KURA. Bank of America lowered their price objective on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Finally, HC Wainwright lifted their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.